The Nihon Kohden Vital Sign Telemeter GZ-140P is intended to monitor and transmit physiological data from a patient to a Nihon Kohden monitor via radiofrequency in the 802.11 band for continuous monitoring. GZ-140P transmits electrocardiogram (ECG), respiration data, blood oxygen saturation (SpO2) and non-invasive blood pressure (NIBP). The device may generate an audible and or visible alarm when an arrhythmia exists, when a measured physiological rate falls outside preset limits, or when a technical error is detected. Furthermore, the device can be configured for use as a temporary simple monitor to display the patient's vital signs on the device screen and generate alarms without transmitting the data to other Nihon Kohden monitor.

The device is intended to be used by qualified medical facility, such as hospital or clinic, on all patient populations including adult, neonate, infant, child, and adolescent subgroups, with the exception of NIBP measurement which is not intended for use on neonates.

Device Description

The Nihon Kohden Vital Sign Telemeter GZ-140P is mainly used as a telemetry system within a medical facility. The device transmits patient's vital signs (ECG, SpO2, respiration, and blood pressure) and alarm information via wireless LAN connection to the central monitoring station. The device can be configured to display the patient's vital signs on the screen and generate alarms and used as a temporary simple monitor.

AI/ML Overview

The provided text describes the Nihon Kohden Vital Sign Telemeter GZ-140P and its substantial equivalence to predicate devices, but it does not contain the specific details required to complete all sections of your request related to acceptance criteria, device performance, and study methodology for an AI/algorithm-based device in the way you've outlined.

The document discusses the device's function (monitoring and transmitting physiological data), its indications for use, and a comparison of its technological characteristics to predicate devices. It mentions that the atrial fibrillation detection algorithm is the same as a previously cleared device (QP-039P, K152305) and that the iNIBP (Inflation Mode) measurement was "validated in the clinical testing (Attachment 015)". However, Attachment 015 and its contents are not provided in this text.

Therefore, I cannot extract specific quantitative acceptance criteria or detailed study results (like sample sizes, expert qualifications, or MRMC study details) for the GZ-140P's arrhythmia detection or NIBP measurement from the provided FDA 510(k) summary letter.

Here's what I can extract and what is missing based on the provided text:

Acceptance Criteria and Reported Device Performance

The document does not explicitly state quantitative acceptance criteria or specific reported device performance metrics in a readily extractable table format for features like arrhythmia detection accuracy or NIBP measurement precision for the GZ-140P itself. It relies on substantial equivalence and reference to previously cleared algorithms/devices.

What is mentioned:

Atrial Fibrillation Detection Algorithm: "is exactly same as that of Nihon Kohden Afib Detection Program QP-039P (K152305)." This implies that the performance of K152305 serves as the reference.
iNIBP (Inflation Mode) Measurement: "was validated in the clinical testing (Attachment 015)." The details of this validation, including performance metrics and acceptance criteria, are contained within Attachment 015, which is not provided.

Feature/Metric	Acceptance Criteria (Not explicitly stated for GZ-140P, relies on predicate)	Reported Device Performance (Not provided for GZ-140P, relies on predicate/unseen attachment)
Arrhythmia Detection (AFib)	Assumed to meet performance of Nihon Kohden Afib Detection Program QP-039P (K152305)	Not detailed in this document.
NIBP Measurement (iNIBP)	Assumed to meet performance validated in clinical testing (Attachment 015) and similar to Welch Allyn Spot Ultra Vital Signs (K040490)	Not detailed in this document.
Other physiological data (ECG, Respiration, SpO2)	Assumed to meet performance of Nihon Kohden BSM-6000 Series Bedside Monitor (K080342) and GZ-120P/GZ-130P (K153707)	Not detailed in this document.

Study Details (Based on available information and inferences)

As the document is a 510(k) summary, it focuses on substantial equivalence rather than a full clinical study report for this specific device's de novo performance. The details you've requested are typically found in the full submission or predicate device's documentation.

Sample size used for the test set and the data provenance:
- Test Set Sample Size: Not specified for the GZ-140P directly. The iNIBP validation was done via "clinical testing (Attachment 015)," but sample size is not stated here.
- Data Provenance: Not explicitly stated (e.g., country of origin, retrospective/prospective). Clinical testing implies prospective collection for that specific validation, but full details are missing.
Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- Not specified in this document. This would be part of the "clinical testing (Attachment 015)" or the study for K152305.
Adjudication method (e.g. 2+1, 3+1, none) for the test set:
- Not specified in this document.
If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- Not indicated. This device is primarily a physiological data acquisition and transmission system with integrated algorithms (like AFib detection). The text does not describe an AI assistance role for human readers or an MRMC study. The AFib detection is a standalone algorithm.
If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
- Yes, implicitly for the AFib detection algorithm. The document states, "The atrial fibrillation detection algorithm is exactly same as that of Nihon Kohden Afib Detection Program QP-039P (K152305)." This implies that the standalone performance of QP-039P was already established and used as justification.
- Not explicitly detailed for NIBP or other measurements beyond mentioning "clinical testing."
The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
- Not specified in this document. For physiological measurements like NIBP, ground truth is typically established by reference measurement devices or highly trained clinicians following specific protocols. For arrhythmia detection, it's typically expert-adjudicated ECG tracings.
The sample size for the training set:
- Not specified. Given that the AFib algorithm is a previously cleared one (K152305), its training would have predated this submission. No information on training data for the GZ-140P itself is provided.
How the ground truth for the training set was established:
- Not specified. This pertains to the development of the QP-039P algorithm or other internal algorithms; details are not in this summary.

In summary, this 510(k) summary relies on demonstrating substantial equivalence to predicate devices and previously cleared algorithms rather than presenting a de novo, detailed performance study for the GZ-140P's integrated functions. The key details about quantitative performance and study methodologies (especially for the atrial fibrillation detection and iNIBP validation) are either assumed based on prior clearances or are contained in referenced attachments not included here.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol that resembles a stylized caduceus or a family of three people.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

April 4, 2017

Nihon Kohden Corporation % Tom Bento Sr. Vice President, Quality And Regulatory Nihon Kohden America, Inc. 15353 Barranca Parkway Irvine, California 92618

Re: K163459 Trade/Device Name: Nihon Kohden Vital Sign Telemeter GZ-140P Regulation Number: 21 CFR 870.1025 Regulation Name: Arrhythmia Detector and Alarm (Including ST-Segment Measurement and Alarm) Regulatory Class: Class II Product Code: MHX Dated: March 7, 2017 Received: March 8, 2017

Dear Tom Bento:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in

{1}------------------------------------------------

the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely.

Minde Jellman
for

Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K163459

Device Name

Nihon Kohden Vital Sign Telemeter GZ-140P

Indications for Use (Describe)

Type of Use (Select one or both, as applicable)
-------------------------------------------------

X Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) Summary

Nihon Kohden Vital Sign Telemeter GZ-140P

Submitter:Address:	Nihon Kohden Corporation1-31-4 Nishiochiai, 1-Chome, Shinjuku-KuTokyo, Japan 161-8560
Phone number:	81-2-59968020
Contact person:Phone number:Fax number:	Tom Bento(949) 680-9048(913) 273-0732
Date prepared:	December 06, 2016
Device name:Common name:Device classification:	Nihon Kohden Vital Sign Telemeter GZ-140PPatient monitorMonitor, physiological, patient (with arrhythmia detection or alarms),Transmitters and Receivers, Physiological Signal, Radio Frequency
Primary Product code:Regulation:	MHX21 CFR 870.1025
Secondary Product Code:Requlation:	DRG21 CFR 870.2910
Substantial equivalentclaimed to:	Nihon Kohden BSM-6000 Series Bedside Monitor (K080342) andNihon Kohden Vital Sign Telemeter GZ-120P and GZ-130P(K153707)

Description:

Indications for Use:

The Nihon Kohden Vital Sign Telemeter GZ-140P is intended to monitor and transmit physiological data from a patient to a Nihon Kohden monitor via radiofrequency in the 802.11 band for continuous monitoring. GZ-140P transmits electrocardiogram (ECG), respiration data, blood oxygen saturation (SpO2) and non-invasive blood pressure (NIBP). The device may generate an audible and/or visible alarm when an arrhythmia exists, when a measured physiological rate falls outside preset limits, or when a technical error is detected. Furthermore, the device can be configured for use as a temporary simple monitor to display the patient's vital signs on the device screen and generate alarms without transmitting the data to other Nihon Kohden monitor.

{4}------------------------------------------------

The device is intended to be used by qualified medical personnel within a medical facility, such as hospital or clinic, on all patient populations including adult, neonate, infant, child, and adolescent subgroups, with the exception of NIBP measurement which is not intended for use on neonates.

Technological Characteristics - Substantial Equivalence Discussion:

The Nihon Kohden Vital Sign Telemeter GZ-140P is substantially equivalent to the predicate devices, Nihon Kohden BSM-6000 Series Bedside Monitor (K080342) and Nihon Kohden Vital Sign Telemeter GZ-120P and GZ-130P. Differences between the devices are minor and do not raise questions reqarding safety or efficacy.

These differences include:

. The GZ-140P is substantially equivalent to the GZ-120P/GZ-130P Vital Sign Telemeter other than the additional functions of NIBP measurement and atrial fibrillation detection.
. The GZ-140P has two NIBP measurement modes: Conventional Mode (Deflation Mode) where NIBP measurements are made during deflation of the cuff and iNIBP (Inflation Mode) where NIBP measurements are made during inflation of the cuff. The Conventional Mode (Deflation Mode) is the same as that of the predicate device, BSM-6000 series bedside monitor. The iNIBP (Inflation Mode) measurement uses the same oscillometric method as the Conventional Mode (Deflation Mode) measurement and was validated in the clinical testing (Attachment 015). The similar technology with iNIBP is acquired by Welch Allyn Spot Ultra Vital Signs (K040490), where the blood pressure is measured while the device is inflating a cuff.
. The atrial fibrillation detection algorithm is exactly same as that of Nihon Kohden Afib Detection Program QP-039P (K152305).

Test Summary:

Performance testing for the Nihon Kohden Vital Sign Telemeter GZ-140P includes software verification and validation test, software unit test, integration test, and testing to compliance standards for electromagnetic safety. Wireless coexistence testing and evaluation was performed following FDA Guidance, "Radio Frequency Wireless Technology in Medical Device", and the device's immunity to proximity fields from radio frequency wireless communications equipment was validated. Traceability has been documented between all system specifications to validation test results.

Standards compliance testing includes:

ANSI/AAMI ES60601-1:2005/(R)2012 and A1:2012: General requirements for basic safety and ● essential performance
IEC 60601-1-2: 2007 Medical Electrical Equipment Part 1-2: General requirements for Basic . Safety and Essential Performance - Collateral Standard: Electromagnetic Compatibility -Requirements and Tests
. IEC 60601-1-8: 2006 & A1:2012 Medical electrical equipment - Part 1-8: General requirements for basic safety and essential performance - collateral standard: General requirements, tests and guidance for alarm systems in medical electrical equipment and medical electrical systems
. IEC 60601-2-27:2011 Medical electrical equipment - Part 2-27: Particular requirements for the basic safety and essential performance of electrocardiographic monitoring equipment

{5}------------------------------------------------

IEC 60601-2-49:2011 Medical electrical equipment Part 2-49: Particular requirements for the . basic safety and essential performance of multifunction patient monitoring equipment
. IEC 80601-2-30:2013 Medical electrical equipment - Part 2-30: Particular requirements for the basic safety and essential performance of automated non-invasive sphygmomanometers
ISO 80601-2-61:2011 Medical electrical equipment - Part 2-61: Particular requirements for the basic safety and essential performance of pulse oximeter equipment
. ISO 81060-2:2013 Non-invasive sphygmomanometers – Part 2: Clinical validation of automated measurement type
ANSI/AAMI EC57:2012 Testing and reporting performance results of cardiac rhythm and STsegment measurement algorithms
. IEC 62304:2006 Medical device software - Software life-cycle processes
. ISO 10993-5:2009 Biological evaluation of medical devices - Part 5: Tests for In Vitro cytotoxicity
. ISO 10993-10:2010 Biological evaluation of medical devices – Part 10: Tests for irritation and skin sensitization
. ISO 14971:2007 Medical devices – Application of risk management to medical devices

Verification and validation testing includes:

. Software Verification and Validation Test
Software Unit Test
. Integration Test
System Test
. Wireless Coexistence Test
. Wireless Design Validation and Verification Test

Conclusion:

The performance of the Nihon Kohden Vital Sign Telemeter GZ-140P is substantially equivalent to the predicate devices, the Nihon Kohden BSM-6000 Series Bedside Monitor (K080342) and the Nihon Kohden Vital Sign Telemeter GZ-120P and GZ-130P (K153707), and raises no safety or effectiveness issues.

Regulation Number and Section

§ 870.1025 Arrhythmia detector and alarm (including ST-segment measurement and alarm).

(a)
Identification. The arrhythmia detector and alarm device monitors an electrocardiogram and is designed to produce a visible or audible signal or alarm when atrial or ventricular arrhythmia, such as premature contraction or ventricular fibrillation, occurs.(b)
Classification. Class II (special controls). The guidance document entitled “Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm” will serve as the special control. See § 870.1 for the availability of this guidance document.